目的 观察双丹明目胶囊联合羟苯磺酸钙分散片治疗糖尿病视网膜病变的安全性和有效性。方法 选取2016年8月—2017年8月大连市第三人民医院接诊的糖尿病视网膜病变患者143例，随机分成对照组（71例）和治疗组（72例）。对照组患者口服羟苯磺酸钙分散片，1片/次，3次/d；治疗组患者在对照组治疗基础上口服双丹明目胶囊，4粒/次，3次/d。两组患者均连续治疗4个月。观察两组患者临床疗效，同时比较治疗前后两组患者低视力者生活质量评分量表（CLVQOL）评分、视野平均缺损程度和证候积分、血清脂联素、胰岛素样生长因子1（IGF-1）、色素上皮衍生因子（PEDF）和不良反应情况。结果 治疗后，对照组临床有效率为84.51%，显著低于治疗组的95.83%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者CLVQOL评分显著升高（P<0.05），视野平均缺损程度和证候积分均显著降低（P<0.05），且治疗组患者CLVQOL评分、视野平均缺损程度、证候积分比对照组改善更明显（P<0.05）。治疗后，两组患者血清脂联素和PEDF水平均显著升高（P<0.05），IGF-1水平显著降低（P<0.05），且治疗组患者血清脂联素、IGF-1及PEDF水平比对照组改善更明显（P<0.05）。治疗期间，治疗组患者不良反应发生率为2.78%，明显低于对照组的12.68%，两组比较差异具有统计学意义（P<0.05）。结论 双丹明目胶囊联合羟苯磺酸钙分散片治疗糖尿病视网膜病变疗效显著，不良反应发生率低，具有一定的临床推广应用价值。

Objective To observe the clinical safety and efficacy of Shuangdan Mingmu Capsules combined with Calcium Dobesilate Dispersible Tablets in treatment of diabetic retinopathy. Methods Patients (143 cases) with diabetic retinopathy in the Third People's Hospital of Dalian from August 2016 to August 2017 were randomly divided into control (71 cases) and treatment (72 cases) groups. Patients in the control group were po administered with Calcium Dobesilate Dispersible Tablets, 1 tablet/time, three times daily. Patients in the treatment group were po administered with Shuangdan Mingmu Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 months. After treatment, the clinical efficacy was evaluated, and the CLVQOL score, mean visual field defect, syndrome scores, serum adiponectin, IGF-1, PEDF and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 84.51%, which was significantly lower than 95.83% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the CLVQOL scores in two groups were significantly increased (P<0.05), but mean visual field defect and syndrome scores were significantly decreased (P<0.05), and these indicators in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the serum adiponectin and PEDF levels in two groups were significantly increased (P<0.05), but IGF-1 levels were significantly decreased (P<0.05), and the serum adiponectin, IGF-1 and PEDF levels in the treatment group were significantly better than those in the control group (P<0.05). During the treatment, the adverse reactions rate in the treatment group was 2.78%, which was significantly lower than 12.68% in the control group, with significant difference between two groups (P<0.05). Conclusion Shuangdan Mingmu Capsules combined with Calcium Dobesilate Dispersible Tablets has significant curative effect in treatment of diabetic retinopathy with low incidence of adverse reactions, which has a certain clinical application value.